Skip to content
Peptide research

Thyreogen

Also known as Thyroid Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

A thyroid-tissue-derived bioregulator peptide, marketed to support and normalize thyroid function in aging adults. The case remains weak: a small institute report includes a comparison group, but robust independent trials are lacking. The bigger concern is safety: interaction with thyroid medications, risk in hyperthyroid conditions, and a smaller allergy risk from bovine-derived material. Not an approved drug in the US, and supply is mainly unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Thyreogen is a natural peptide bioregulator derived from the thyroid gland of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets the thyroid gland, where it is designed to exert tissue-specific effects on thyroid cells, restoring disturbed thyroid tissue function and normalizing hormone production. It is closely related to Thyramin, another thyroid-targeting peptide bioregulator with a PubMed-indexed clinical study.

Thyroid gland pathology is one of the most widespread endocrine disorders, with age being a major risk factor for developing hypothyroid states. A PubMed-indexed study (PMID 16075681) describes the efficacy of peptide bioregulators in correcting reduced thyroid function, noting that Thyramin (the related bioregulator) exerts tissue-specific effects on thyroid gland cells and enables restoration of disturbed thyroid function, particularly in elderly patients where subclinical and manifest hypothyroidism affect quality of life.

Thyreogen is manufactured in capsule form and is marketed for supporting thyroid function during aging, environmental stress (particularly in iodine-deficient regions), and as part of comprehensive bioregulator anti-aging protocols. It addresses the endocrine component alongside Endoluten (pineal), Glandokort (adrenal), and other gland-specific bioregulators.

How it works in the body

A bioregulator peptide complex derived from thyroid tissue. It regulates gene expression in thyroid follicular cells involved in thyroid hormone (T3/T4) synthesis and secretion, helping normalize thyroid function without directly replacing hormones.

Research overview

Thyreogen shares its research base with Thyramin, a related thyroid peptide bioregulator. PMID 16075681 describes peptide bioregulator efficacy in correcting reduced thyroid function, highlighting the tissue-specific effects on thyroid cells and restoration of disturbed function. The broader Khavinson research program provides context on how organ-specific peptides regulate gene expression in targeted tissues. Thyreogen specifically is classified as a Cytomaxes (natural extract) while Thyramin is a related product line. Clinical evidence is limited to Russian studies on thyroid peptide bioregulators in elderly patients with hypothyroid states.

Who researches Thyreogen?

Commonly researched by

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching support for thyroid function in age-related hypothyroidism

    One of the primary studied benefits of Thyreogen.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Interaction with thyroid medications

    Moderate

    PMID 30567254; PMID 26895744

  • Risk in hyperthyroid conditions

    Moderate

    PMID 26895744

  • Allergic reaction to bovine thyroid-derived peptides

    Low

    No published case reports; category-level reasoning

Interaction summary(8)

Rated by direction with this peptide

  • Levothyroxine (T4)

    CautionModerate

    Bovine thyroid-derived supplements have been found to contain unlabeled active thyroid hormone, so co-use risks additive over-replacement and iatrogenic thyrotoxicosis; check TSH/free T4 before and 6-8 weeks after starting.

    PMID 26895744; PMID 30567254

  • Liothyronine (T3) and desiccated thyroid extract (NDT)

    CautionModerate

    Same additive-hormone concern as levothyroxine but amplified, since T3-containing regimens already produce supraphysiologic post-dose peaks and leave less margin before symptomatic thyrotoxicosis.

    PMID 30567254

  • Antithyroid drugs (methimazole, carbimazole, propylthiouracil)

    CautionTheoretical

    The product's claimed action - restoring follicular-cell hormone synthesis - runs directly counter to the therapeutic goal of thionamide therapy, and any hormone contamination would blunt titration; no interaction study exists.

    Mechanism-based (PMID 16075681 describes the intended thyroid-stimulating direction)

  • Radioactive iodine (I-131) therapy and iodinated contrast/amiodarone

    CautionTheoretical

    Undeclared iodine or thyroid hormone in an animal-tissue extract could alter thyroidal iodine uptake and confound I-131 dosimetry or post-treatment thyroid function assessment; discontinue well before scanning or ablation.

    Mechanism-based; no published data on Thyreogen iodine content

  • Warfarin and other vitamin K antagonists

    CautionTheoretical

    Any shift in thyroid status changes clotting-factor turnover and warfarin sensitivity - a well-established effect of thyroid hormone therapy - so INR should be watched if thyroid parameters move on this product.

    Class effect of thyroid-status change; not studied for Thyreogen

  • Insulin and oral antihyperglycemics

    CautionTheoretical

    Improving or destabilizing thyroid status alters insulin clearance and hepatic glucose output, so glycemic control may drift and require dose review; no direct data for this peptide.

    Class effect of thyroid-status change; not studied for Thyreogen

  • Beta-blockers (propranolol, atenolol)

    NeutralLow

    No pharmacokinetic interaction is expected, but beta-blockade can mask the adrenergic symptoms (tachycardia, tremor) that would otherwise be the first warning of hormone over-exposure from a contaminated glandular product.

    Mechanism-based; no published interaction data

  • Thyroid function testing (TSH, free T4, thyroglobulin assays)

    CautionLow

    Not a drug interaction but a clinically important one: unregulated glandular content can suppress TSH and distort interpretation of thyroid panels and thyroglobulin surveillance, so disclose use to the ordering clinician.

    PMID 26895744

Known risks(3)

  • Interaction with thyroid medications

    Moderate

    Thyroid-targeting peptides could theoretically affect thyroid hormone levels, potentially requiring adjustment of levothyroxine or other thyroid medications.

  • Risk in hyperthyroid conditions

    Moderate

    Should not be used in uncontrolled hyperthyroidism without medical supervision.

  • Allergic reaction to bovine thyroid-derived peptides

    Low

    Theoretical risk; no serious adverse events reported.

Drug interactions(2)

  • Levothyroxine and other thyroid hormones

    Potential interaction; monitor TSH and thyroid levels closely

  • Antithyroid drugs (methimazole, PTU)

    Theoretical antagonism; avoid concurrent use without medical supervision

Research & benefits

Evidence base

Evidence Level
Very Limited Evidence
Total Studies
3
Human Studies
50

Evidence includes a PubMed-indexed controlled clinical trial of the related Thyramin product (PMID 16075681) and Khavinson Institute reports. Direct clinical data for Thyreogen capsules specifically is minimal. The evidence base relies on extrapolation from the related Thyramin product and the general bioregulator research program.

Researched for(3)

Rated by confidence in the evidence

  • Support for thyroid function in age-related hypothyroidism

    Speculative

    Evidence includes related-product research and a small institute report on oral Thyreogen; independent confirmation is lacking.

    PMID 16075681

  • Thyroid cell metabolism normalization

    Speculative

    Mechanism-based only, no study of Thyreogen's effect on thyroid cell activity.

    PMID 34834147; PMID 31808038

  • Endocrine system support in aging

    Speculative

    Extrapolated from other peptide bioregulators, no controlled human data for Thyreogen.

    PMID 11452647; PMID 25306656

Benefits(3)

  • Support for thyroid function in age-related hypothyroidism

    PMID 16075681 (Thyramin/thyroid bioregulator review)

  • Thyroid cell metabolism normalization

    Khavinson Institute research program; tissue-specific peptide data

  • Endocrine system support in aging

    Khavinson bioregulator research; used in comprehensive endocrine protocols

Key studies(1)

  1. Khavinson VKh et al.

    Advances in Gerontology

    2005

    Thyroid peptide bioregulators (Thyramin) show tissue-specific effects on thyroid cells and enable restoration of disturbed thyroid function, particularly important in elderly patients with subclinical and manifest hypothyroidism.

Regulation & availability

Why researchers look at it

Thyreogen targets thyroid cell function with organ-specific peptides, addressing one of the most common age-related endocrine disorders. It is part of Khavinson's comprehensive endocrine bioregulator system alongside Endoluten and Glandokort.

Estimated cost
$30-60/mo (capsules)
FDA status
Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
WADA status
Not individually named. WADA S0 prohibits pharmacological substances not covered by later sections of the List that lack current approval from any governmental health authority for human therapeutic use. Supplement registration does not establish that approval; product-specific anti-doping confirmation is needed.
Prescribability
Available in Russia as dietary supplement; not approved in USA/EU
Availability
Manufactured by GARMONIA Ltd. Not available through conventional pharmacies in USA/EU.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(2)

  1. 2000s
    Developed and commercialized as Cytomaxes supplement in Russia
  2. 2005
    PubMed-indexed controlled clinical trial of the related thyroid bioregulator Thyramin published

Sources & FAQs

Research sources(2)

Frequently asked questions(3)

Can Thyreogen replace thyroid medication?

No. Thyreogen is a dietary supplement, not a drug. It should not replace prescribed thyroid medications like levothyroxine. Patients on thyroid medication should consult their endocrinologist before adding any thyroid-targeting supplement.

Is Thyreogen safe for people with hyperthyroidism?

Thyreogen is described as normalizing (regulatory) rather than purely stimulatory. However, individuals with hyperthyroidism or Graves' disease should exercise extreme caution and consult an endocrinologist, as thyroid-targeting peptides could theoretically exacerbate overactive thyroid conditions.

How is Thyreogen related to Thyramin?

Both target the thyroid gland. Thyreogen is classified as a Cytomaxes (natural peptide complex from animal thyroid tissue), while Thyramin is a related product from the same research program. They share the same mechanistic basis.